UroGen Pharma
URGN | NASDAQ
$28.10
+$1.92 (+7.33%)
At close: Nov 16, 2026, 4:00 PM ET
$27.54
-$0.56 (-1.99%)
After-hours:
Nov 16, 2026, 7:30 PM ET
UroGen Pharma Company Profile
Company profile explainedCompany Profile
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Elizabeth A. Barrett | President, Chief Executive Officer & Director |
| Christopher Degnan | Chief Financial Officer |
| Alison Hardgrove | Senior Vice President of Human Resources |
| James Ottinger | Executive Vice President of Regulatory Affairs & Quality |
| Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary |
| Marina Konorty | Executive Vice President of Research & Development and Technical Operations |
| Mark Schoenberg | Chief Medical Officer |
| Michael J. Louie | Chief Development Officer |
| Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy |
| Vincent I. Perrone | Senior Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 20, 2026 | 8-K | Current Report |
| Aug 12, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
UroGen Pharma
| Country | United States |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Elizabeth Barrett |
Contact Details
400 Alexander Park Drive Princeton,
New Jersey 08540 United States
Stock Details
| Ticker Symbol | URGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668243 |
| CUSIP Number | n/a |
| ISIN Number | IL0011407140 |
| SIC Code | 2834 |
Recent News
- 8 days ago / seekingalpha.comUroGen: Opportunity Builds As Rough Patch Gets Brutal
- 12 days ago / marketbeat.comUrogen Pharma Q3 Earnings Call Highlights
- 12 days ago / fool.comThe Gel That Became a Business
- 12 days ago / seekingalpha.comUroGen Pharma Ltd. (URGN) Q3 2026 Earnings Call Transcript
- 13 days ago / zacks.comUrogen Pharma (URGN) Reports Q3 Loss, Beats Revenue Estimates
- 13 days ago / globenewswire.comUroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
- 14 days ago / globenewswire.comUroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
- 15 days ago / globenewswire.comUroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
- 20 days ago / globenewswire.comUroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
- 29 days ago / globenewswire.comUroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Add to Watchlist
Select watchlists to add or remove URGN